BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17680018)

  • 1. Treatment strategies for bone disease.
    Roodman GD
    Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New potential targets for treating myeloma bone disease.
    Roodman GD
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
    Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
    Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of myeloma bone disease.
    Roodman GD
    Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dickkopf-1: a suitable target for the management of myeloma bone disease.
    Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
    Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
    Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
    Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of multiple myeloma bone disease.
    Lentzsch S; Ehrlich LA; Roodman GD
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloma bone disease and treatment options.
    Yeh HS; Berenson JR
    Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approaches to myeloma bone disease: an evolving story.
    Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
    Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
    Zannettino AC; Farrugia AN; To LB; Atkins GJ
    Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone markers in multiple myeloma.
    Heider U; Fleissner C; Zavrski I; Kaiser M; Hecht M; Jakob C; Sezer O
    Eur J Cancer; 2006 Jul; 42(11):1544-53. PubMed ID: 16765040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the microenvironment in multiple myeloma bone disease.
    Huston A; Roodman GD
    Future Oncol; 2006 Jun; 2(3):371-8. PubMed ID: 16787117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
    Roodman GD; Dougall WC
    Cancer Treat Rev; 2008 Feb; 34(1):92-101. PubMed ID: 17964729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloma bone disease.
    Sezer O
    Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloma bone disease: pathogenetic mechanisms and clinical assessment.
    Silvestris F; Lombardi L; De Matteo M; Bruno A; Dammacco F
    Leuk Res; 2007 Feb; 31(2):129-38. PubMed ID: 16764925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloma bone disease: pathogenesis, current treatments and future targets.
    Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
    Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms for formation of myeloma bone disease].
    Yata K; Abe M; Matsumoto T
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.